# Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

> **NCT00793871** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 60 (actual)

## Conditions studied

- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Sunitinib Malate (SU011248)

## Key facts

- **NCT ID:** NCT00793871
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2014-04
- **Final completion:** 2014-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793871, "Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00793871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*